|
Treatment
| |
---|
Characteristics
|
2 mg/kg (n = 53)
|
4 mg/kg (n = 54)
|
8 mg/kg (n = 52)
|
2 mg/kg + MTX (n = 52)
|
4 mg/kg + MTX (n = 49)
|
8 mg/kg + MTX (n = 50)
|
MTX (n = 49)
|
All groups (n = 359)
|
---|
Age (years)
|
52.2
|
49.3
|
50.1
|
49.2
|
50.2
|
50.1
|
50.9
|
50.3
|
Sex (male/female)
|
9/44
|
13/41
|
14/38
|
7/45
|
12/37
|
11/39
|
11/38
|
77/282
|
Duration of RA (years)
|
9.19
|
9.79
|
9.21
|
9.33
|
7.82
|
10.62
|
11.24
|
-
|
TJC (28)
|
15
|
15
|
15
|
15
|
13
|
15
|
16
|
15
|
SJC (28)
|
11
|
11
|
12
|
11
|
11
|
11
|
12
|
11
|
ESR (mm/hour)
|
39a
|
41
|
39b
|
45c
|
40
|
39d
|
43
|
41
|
CRP (mg/l)
|
26a
|
19
|
22b
|
28c
|
31
|
24d
|
32
|
27
|
DAS28
|
6.48a
|
6.55
|
6.43b
|
6.58c
|
6.34
|
6.47d
|
6.75
| |
RF positive (n)
|
44
|
39
|
43
|
46
|
38
|
40
|
47
| |
- an = 52; bn = 51; cn = 50; dn = 49. CRP, C-reactive protein; DAS28, Disease Activity Score; ESR, erythrocyte sedimentation rate; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; SJC, swollen joint count; TJC, total joint count. Reproduced, with permission, from [13].